A controlled trial of nandrolone decanoate in the treatment of rheumatoid arthritis in postmenopausal women. 1987

H A Bird, and L Burkinshaw, and D Pearson, and P J Atkinson, and P A Leatham, and J Hill, and A Raven, and V Wright

To determine whether an anabolic steroid had any benefit in the treatment of rheumatoid arthritis 47 patients entered a parallel group study. Twenty four received nandrolone decanoate 50 mg intramuscularly every third week for two years and 23 patients received no anabolic steroids. Other therapy was unaltered. Patients attended for clinical and biochemical assessments as well as the objective assessments of elementary body composition by in vivo neutron activation analysis and measurement of the mineral content of the distal femur by single photon absorptiometry on five occasions. A modest clinical deterioration (except for grip strength) was seen in both groups. No significant changes in calcium or alkaline phosphatase were seen. There was no significant change in total body calcium, total body phosphorus, body weight, or bone index/bone width measurements in either group. Significant increases occurred in total body nitrogen, total body potassium, haemoglobin, and packed cell volume (by six months) in the group treated with nandrolone decanoate. Comparison of 10 patients in the group treated with nandrolone decanoate also receiving oral steroid therapy with 14 patients in this group not receiving oral steroid therapy showed no significant differences. The main side effect of nandrolone decanoate was hoarseness. No radiological changes were seen. Nandrolone decanoate, in a dose that produces a significant anabolic effect, has no demonstrable action on bone metabolism in rheumatoid arthritis but may improve the chronic anaemia by six months.

UI MeSH Term Description Entries
D008593 Menopause The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age. Change of Life, Female
D009277 Nandrolone C18 steroid with androgenic and anabolic properties. It is generally prepared from alkyl ethers of ESTRADIOL to resemble TESTOSTERONE but less one carbon at the 19 position. 19-Nortestosterone,Estrenolone,Norandrostenolone,Nortestosterone,17-Hydroxy-Estr-4-Ene-3-One,17beta-Hydroxy-19-Nor-4-Androsten-3-One,17beta Hydroxy 19 Nor 4 Androsten 3 One
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077603 Nandrolone Decanoate Decanoic acid ester of nandrolone that is used as an anabolic agent to prevent or treat WASTING SYNDROME associated with severe chronic illness or HIV infection (HIV WASTING SYNDROME). It may also be used in the treatment of POSTMENOPAUSAL OSTEOPOROSIS. 17 beta-Hydroxyestr-4-en-3-one 17-decanoate,19-Nortestosterone Decanoate,19-nor-4-Androstene-17 beta-ol-3-one 17-decanoate,Decadurabolin,Decadurobolin,Retabolil,Retabolyl,17 beta Hydroxyestr 4 en 3 one 17 decanoate,19 Nortestosterone Decanoate,19 nor 4 Androstene 17 beta ol 3 one 17 decanoate
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis
D045930 Anabolic Agents These compounds stimulate anabolism and inhibit catabolism. They stimulate the development of muscle mass, strength, and power. Anabolic Effect,Anabolic Effects,Agents, Anabolic,Effect, Anabolic,Effects, Anabolic

Related Publications

H A Bird, and L Burkinshaw, and D Pearson, and P J Atkinson, and P A Leatham, and J Hill, and A Raven, and V Wright
June 1998, Indian journal of medical sciences,
H A Bird, and L Burkinshaw, and D Pearson, and P J Atkinson, and P A Leatham, and J Hill, and A Raven, and V Wright
January 1963, Neurology,
H A Bird, and L Burkinshaw, and D Pearson, and P J Atkinson, and P A Leatham, and J Hill, and A Raven, and V Wright
April 1989, Bone and mineral,
H A Bird, and L Burkinshaw, and D Pearson, and P J Atkinson, and P A Leatham, and J Hill, and A Raven, and V Wright
January 1993, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA,
H A Bird, and L Burkinshaw, and D Pearson, and P J Atkinson, and P A Leatham, and J Hill, and A Raven, and V Wright
April 1999, JAMA,
H A Bird, and L Burkinshaw, and D Pearson, and P J Atkinson, and P A Leatham, and J Hill, and A Raven, and V Wright
January 1998, Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti,
H A Bird, and L Burkinshaw, and D Pearson, and P J Atkinson, and P A Leatham, and J Hill, and A Raven, and V Wright
January 1989, Archives of internal medicine,
H A Bird, and L Burkinshaw, and D Pearson, and P J Atkinson, and P A Leatham, and J Hill, and A Raven, and V Wright
January 1989, Minerva endocrinologica,
H A Bird, and L Burkinshaw, and D Pearson, and P J Atkinson, and P A Leatham, and J Hill, and A Raven, and V Wright
July 1987, Calcified tissue international,
H A Bird, and L Burkinshaw, and D Pearson, and P J Atkinson, and P A Leatham, and J Hill, and A Raven, and V Wright
October 1997, Scandinavian journal of clinical and laboratory investigation,
Copied contents to your clipboard!